vs
Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $103.7M, roughly 1.0× Twist Bioscience Corp). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -29.4%, a 56.0% gap on every dollar of revenue.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
OBK vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $103.7M |
| Net Profit | $27.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | 26.6% | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $0.89 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $103.4M | $103.7M | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $83.5M | — | ||
| Q1 25 | $94.1M | — | ||
| Q4 24 | $78.3M | — | ||
| Q3 24 | $90.8M | — | ||
| Q2 24 | $96.4M | — |
| Q1 26 | $27.7M | — | ||
| Q4 25 | $29.5M | $-30.5M | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $14.6M | — | ||
| Q1 25 | $22.4M | — | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $18.6M | — | ||
| Q2 24 | $21.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 36.2% | -31.7% | ||
| Q3 25 | 10.0% | — | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 26.1% | — | ||
| Q2 24 | 27.7% | — |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.5% | -29.4% | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | 18.2% | — | ||
| Q3 24 | 20.5% | — | ||
| Q2 24 | 21.8% | — |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.95 | $-0.50 | ||
| Q3 25 | $0.27 | — | ||
| Q2 25 | $0.47 | — | ||
| Q1 25 | $0.71 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.60 | — | ||
| Q2 24 | $0.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $456.1M |
| Total Assets | $10.2B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $424.2M | $197.9M | ||
| Q3 25 | $626.9M | — | ||
| Q2 25 | $334.1M | — | ||
| Q1 25 | $486.2M | — | ||
| Q4 24 | $470.2M | — | ||
| Q3 24 | $321.2M | — | ||
| Q2 24 | $288.1M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $456.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $9.7B | $638.1M | ||
| Q3 25 | $9.8B | — | ||
| Q2 25 | $9.7B | — | ||
| Q1 25 | $9.8B | — | ||
| Q4 24 | $9.7B | — | ||
| Q3 24 | $10.0B | — | ||
| Q2 24 | $9.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $158.9M | $-24.8M | ||
| Q3 25 | $59.3M | — | ||
| Q2 25 | $20.6M | — | ||
| Q1 25 | $35.6M | — | ||
| Q4 24 | $108.5M | — | ||
| Q3 24 | $39.6M | — | ||
| Q2 24 | $11.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $151.1M | $-34.8M | ||
| Q3 25 | $56.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q1 25 | $34.8M | — | ||
| Q4 24 | $86.4M | — | ||
| Q3 24 | $32.2M | — | ||
| Q2 24 | $6.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 146.0% | -33.5% | ||
| Q3 25 | 51.7% | — | ||
| Q2 25 | 23.5% | — | ||
| Q1 25 | 37.0% | — | ||
| Q4 24 | 110.3% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 6.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 9.6% | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 5.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.38× | — | ||
| Q3 25 | 6.88× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 7.60× | — | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
